AI assistant
Sending…
C4 Therapeutics, Inc. — Director's Dealing 2021
Nov 19, 2021
33861_dirs_2021-11-19_d795c50c-12c7-4412-a520-6298b52b4657.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-11-19
Reporting Person: Salter Malcolm (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-19 | Common Stock | S | 755 | $40.11 | Disposed | 11707 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021.
More from C4 Therapeutics, Inc.
Board/Management Information
2026
May 15
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Board/Management Information
2026
Apr 10
Capital/Financing Update
2026
Apr 9
Annual Report
2026
Feb 26
Earnings Release
2026
Feb 26
Director's Dealing
2026
Feb 18